CNSX:THC

Stock Analysis Report

Executive Summary

THC Biomed Intl Ltd. produces and sells medical marijuana in Canada.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • THC Biomed Intl has significant price volatility in the past 3 months.
  • THC Biomed Intl is not covered by any analysts.

Share Price & News

How has THC Biomed Intl's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-8.6%

CNSX:THC

-6.0%

CA Pharmaceuticals

-1.2%

CA Market


1 Year Return

-82.6%

CNSX:THC

-22.8%

CA Pharmaceuticals

-4.6%

CA Market

THC underperformed the Pharmaceuticals industry which returned -16.9% over the past year.

THC underperformed the Market in Canada which returned -4.4% over the past year.


Share holder returns

THCIndustryMarket
7 Day-8.6%-6.0%-1.2%
30 Day-20.0%-10.0%-3.0%
90 Day-40.7%-30.2%-3.3%
1 Year-82.6%-82.6%-22.4%-22.8%-1.2%-4.6%
3 Year-40.7%-40.7%382.2%380.3%13.5%3.5%
5 Yearn/a367.1%367.1%12.2%-3.5%

Price Volatility Vs. Market

How volatile is THC Biomed Intl's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is THC Biomed Intl undervalued based on future cash flows and its price relative to the stock market?

1.49x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for THC Biomed Intl to establish if it is available at moderate discount.

Unable to calculate intrinsic value for THC Biomed Intl to establish if it is available at substantial discount.


Price Based on Earnings

THC Biomed Intl is loss making, we can't compare its value to the CA Pharmaceuticals industry average.

THC Biomed Intl is loss making, we can't compare the value of its earnings to the Canada market.


Price Based on Expected Growth

Unable to calculate PEG ratio for THC Biomed Intl, we can't assess if its growth is good value.


Price Based on Value of Assets

THC Biomed Intl is good value based on assets compared to the CA Pharmaceuticals industry average.


Next Steps

Future Growth

How is THC Biomed Intl expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

104.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as THC Biomed Intl has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has THC Biomed Intl performed over the past 5 years?

-55.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

THC Biomed Intl does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare THC Biomed Intl's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare THC Biomed Intl's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if THC Biomed Intl has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if THC Biomed Intl has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if THC Biomed Intl improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is THC Biomed Intl's financial position?


Financial Position Analysis

THC Biomed Intl is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

THC Biomed Intl's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

THC Biomed Intl's level of debt (10%) compared to net worth is satisfactory (less than 40%).

Unable to establish if THC Biomed Intl's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 4.4x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

THC Biomed Intl has less than a year of cash runway based on current free cash flow.

THC Biomed Intl has less than a year of cash runway if free cash flow continues to grow at historical rates of 77.2% each year.


Next Steps

Dividend

What is THC Biomed Intl's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate THC Biomed Intl's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate THC Biomed Intl's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as THC Biomed Intl has not reported any payouts.

Unable to verify if THC Biomed Intl's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as THC Biomed Intl has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of THC Biomed Intl's salary, the management and board of directors tenure and is there insider trading?

4.6yrs

Average board tenure


CEO

John Miller 0

0.0yrs

Tenure

CA$62,400

Compensation

Mr. John Miller serves as Chief Executive Officer and President of THC Biomed Intl Ltd. and its Director since June 3, 2014. 


CEO Compensation Analysis

John's remuneration is lower than average for companies of similar size in Canada.

John's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

4.6yrs

Average Tenure

The tenure for the THC Biomed Intl board of directors is about average.


Insider Trading

More shares have been bought than sold by THC Biomed Intl individual insiders in the past 3 months.


Recent Insider Transactions

BuyCA$7,45305 Jun 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares25,000
Max PriceCA$0.30
BuyCA$9,13504 Jun 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares31,500
Max PriceCA$0.29
BuyCA$48,05403 Jun 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares170,500
Max PriceCA$0.29
BuyCA$14,08701 Jun 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares50,000
Max PriceCA$0.28
BuyCA$22,00229 May 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares77,500
Max PriceCA$0.28
BuyCA$42,27028 May 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares145,500
Max PriceCA$0.29
SellCA$84,60003 Apr 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares250,000
Max PriceCA$0.35
SellCA$21,48702 Apr 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares63,500
Max PriceCA$0.34
SellCA$45,61701 Apr 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares130,000
Max PriceCA$0.35
SellCA$71,58030 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares200,000
Max PriceCA$0.36
SellCA$63,60027 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares170,000
Max PriceCA$0.38
SellCA$19,25026 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares50,000
Max PriceCA$0.38
SellCA$54,20825 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares138,500
Max PriceCA$0.40
SellCA$24,20022 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares60,500
Max PriceCA$0.40
SellCA$154,00019 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares385,000
Max PriceCA$0.40
SellCA$171,93416 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares425,000
Max PriceCA$0.42
SellCA$10,00020 Jan 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares20,000
Max PriceCA$0.50

Ownership Breakdown


Management Team

  • Dianne Szigety (65yo)

    Corporate Secretary

    • Tenure: 3.7yrs
  • Jung Hee

    Co-Founder

    • Tenure: 5.2yrs
    • Compensation: CA$62.40k
  • John Miller

    Chief Executive Officer

    • Tenure: 0.0yrs
    • Compensation: CA$62.40k
  • Damien Reynolds

    Chief Capital Markets Officer

    • Tenure: 4.1yrs

Board Members

  • Jason Springett

    Member of Advisory Board

    • Tenure: 4.1yrs
  • Don Shaxon

    Member of Advisory Board

    • Tenure: 4.1yrs
  • Jung Hee

    Co-Founder

    • Tenure: 5.2yrs
    • Compensation: CA$62.40k
  • John Miller

    Chief Executive Officer

    • Tenure: 0.0yrs
    • Compensation: CA$62.40k

Company Information

THC Biomed Intl Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: THC Biomed Intl Ltd.
  • Ticker: THC
  • Exchange: CNSX
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$24.459m
  • Shares outstanding: 152.87m
  • Website: https://www.thcbiomed.com

Number of Employees


Location

  • THC Biomed Intl Ltd.
  • 1340 St. Paul Street
  • Kelowna
  • British Columbia
  • V1Y 2E1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TFHDDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 1988
THCCNSX (Canadian National Stock Exchange)YesCommon SharesCACADSep 1988
TFHDDB (Deutsche Boerse AG)COM NPVDEEURApr 2015

Biography

THC Biomed Intl Ltd. produces and sells medical marijuana in Canada. It also conducts research and development of the products and services related to cannabis for medical purposes. The company was founded ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 00:46
End of Day Share Price2019/08/16 00:00
Earnings2019/04/30
Annual Earnings2018/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.